natgillin/translations-raw huggingface dataset:
rifampicin, clarithromycin, telithromycin (antibiotika, der anvendes til behandling af infektioner),
rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),
rifampicin, der anvendes til behandling af tuberkulose.
rifampicin, used to treat tuberculosis.
Rifampicin, en stærk CYP3A/CYP2C9-enzyminduktor, reducerede AUC for ospemifen med 58%.
Rifampicin, a strong CYP3A / CYP2C9 enzyme inducer, decreased the AUC of ospemifene by 58%.
rifampicin, et antibiotikum, som bruges til at behandle bakterie-infektioner
rifampicin, an antibiotic used to treat bacterial infections carbamazepine, phenytoin or phenobarbital used to treat epilepsy
rifampicin, et lægemiddel, der anvendes til at forebygge og behandle tuberkulose og andre infektioner
rifampicin, a medicine used to prevent and treat tuberculosis and other infections
Rifampicin, perikon.
Rifampicin, St. John’s wort.
Rifampicin, rifabutin (bruges til at behandle tuberkulose)
Rifampicin, rifabutin (used to treat tuberculosis)
rifampicin, rifabutin eller isoniazid (anvendes til behandling af tuberkulose)
Rifampicin, rifabutin or isoniazid (used to treat tuberculosis);
rifampicin, rifabutin eller rifapentin, antibiotika mod tuberkulose
rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis
rifampicin, rifabutin eller rifapentin, antibiotika til behandling af tuberkulose
rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis
rifampicin, rifabutin – antibiotika (bruges til at behandle infektioner) carbamazepin, phenobarbital, phenytoin –anti-epileptika (bruges til at behandle epilepsi og anfald)
rifampicin, rifabutin – antibiotics (used to treat infections) carbamazepine, phenobarbital, phenytoin –anti-epileptics (used to treat epilepsy and seizures)
rifampicin, rifabutin, der bruges til behandling af tuberkulose
rifampicin, rifabutin, used for tuberculosis,
rifampicin, rifapentin (medicin til behandling af visse infektioner, der skyldes bakterier, såsom tuberkulose).
rifampicin, rifapentine (medicines to treat some bacterial infections such as tuberculosis)
rifampicin, som bruges til at behandle tuberkulose eller meningitis naturlægemidler, som indeholder perikon (Hypericum perforatum), som bruges til at behandle lettere eller moderate depressioner.
rifampicin, used to treat tuberculosis or meningitis, herbal preparation containing hypericum perforatum (St John’s wort) used to treat minor to moderate depression.
Rifampicin, som er en P-gp- induktor, nedsatte aliskirens biotilgængelighed med omkring 50 % i kliniske studier.
Rifampicin, which is an inducer of P-gp, reduced aliskiren bioavailability by approximately 50% in a clinical study.
Rifampicin, som er et antibiotikum, der bruges til at behandle tuberkulose.
Rifampicin, an antibiotic used to treat tuberculosis.
Rifampicin/efavirenz
Rifabutin/Efavirenz
Rifampicin/tenofovirdisoproxilfumarat (600 mg q.d./300 mg q.d.)
Rifampicin/Tenofovir disoproxil fumarate (600 mg q.d./300 mg q.d.)
Rifampicin1
(DXM)
Rifampicin: Samtidig administration af bosentan 125 mg 2 gange dagligt og rifampicin, en potent inducer af CYP2C9 og CYP3A4, til 9 raske forsøgspersoner i 7 dage reducerede plasmakoncentrationen af bosentan med 58%; i et enkelt tilfælde op til næsten 90%.
Rifampicin: co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily with rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of bosentan by 58%, and this decrease could achieve almost 90% in an individual case.
Rifampicin: Ved præmedicinering med induktoren rifampicin i en dosis på 600 mg én gang dagligt i 7 dage sås et fald i Cmax og i AUC af dabigatran på henholdsvis 65,5 % og 67 %.
Rifampicin: Pre-dosing of the probe inducer rifampicin at a dose of 600 mg once daily for 7 days decreased total dabigatran peak and total exposure by 65.5 and 67 %, respectively.
Rifampicinf (600 mg enkeltdosis)
Rifampicinf (600 mg single dose)
Rifampicinkoncentrationer er ikke målt
Rifampicin concentrations not measured
rifampin (medicin til behandling af tuberkulose og nogle andre infektionstyper)
rifampin (used to treat tuberculosis and some other infections)
Rifampin Isoniazid
Rifampicin Isoniazid
rifampin – til behandling af tuberkulose warfarin - til forebyggelse og behandling af blodpropper i ben, lunger, hjerne og hjerte.
rifampin – to treat tuberculosis warfarin – to prevent and treat blood clots forming in the legs, lungs, brain and heart.
Rifampin, en hæmmer af OATP’er og en CYP2C9-induktor, formindskede lesinurad-eksponeringen og reducerede mængden af lesinurad, der udskiltes uomdannet i urinen, en anelse uden nogen klinisk relevant effekt.
Rifampin, an inhibitor of OATPs and an inducer of CYP2C9, decreased lesinurad exposure and slightly reduced the amount of lesinurad excreted unchanged in urine with no clinically relevant effect.
Rifamycin antibakterielle midler (rifampicin, rifabutin), visse antiepileptika (phenytoin, carbamazepin, phenobarbital, primidon) og efavirenz
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz
Rifamycin antibakterielle midler (rifampicin, rifabutin), visse antiepileptika (phenytoin, carbamazepin, phenobarbital, primidon) og efavirenz
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz.
rifamycin-resistens og
and appropriate medical
rifamycin-resistens og
Benzodiazepines
rifamycinresistens og
leading to a risk of rifamycin
rifapentin (antibiotikum, der anvendes til behandling af infektioner, herunder tuberkulose)
rifapentine (antibiotic used to treat infections, including tuberculosis);
Rift eller hul eller blødning i din mave eller tarmene, inflammation eller rift i endetarmsåbningen, koagler (størknet blod) i lungerne, blødninger i lungerne eller luftrøret
Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, blood clots in lungs, bleeding in lungs or trachea (airway)
Rift i nethinde-pigment-epitelet vides at være forbundet med våd AMD; kun observeret hos patienter med våd AMD.
Conditions known to be associated with wet AMD; observed in wet AMD patients only.
Rift i nethinden†
Retinal tear
Rifter i skeden
Vaginal tears
Rigor
1 (0.3)
Rigtige overfølsomhedsreaktioner er sjældne.
True hypersensitivity reactions are rare.
RIGTIGT FORKERT
CORRECT INCORRECT
Rijvaardigheid en het gebruik van machines
Driving and using machines
Rilonacept Regeneron 80 mg/ml pulver og solvens til injektionsvæske, opløsning.
Rilonacept Regeneron 80 mg/ml powder and solvent for solution for injection.
Rilonacept Regeneron 80 mg/ml pulver til injektionsvæske, opløsning rilonacept
Rilonacept Regeneron 80 mg/ml powder for solution for injection rilonacept
Rilonacept Regeneron bør ikke gives hyppigere end én gang om ugen.
Rilonacept Regeneron should not be given more often than once weekly.
Rilonacept Regeneron er ikke blevet undersøgt hos patienter med nedsat leverfunktion.
Rilonacept Regeneron has not been studied in patients with hepatic impairment.
Rilonacept Regeneron er ikke undersøgt hos patienter med nedsat leverfunktion.
Rilonacept Regeneron has not been studied in patients with hepatic impairment.
Rilonacept Regeneron er indiceret til behandling af kryopyrin-associerede periodiske syndromer (CAPS) med svære symptomer, herunder familiært kulde autoinflammatorisk syndrom (FCAS) og Muckle-Wells syndrom (MWS) hos voksne og børn i alderen 12 år og derover.
Rilonacept Regeneron is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older.
Rilonacept Regeneron injiceres i vævet lige under huden.
Rilonacept Regeneron is injected into the tissue directly below the layers of skin.
Rilonacept Regeneron leveres som et pulver til opløsning til injektionsvæske i et hætteglas.
Rilonacept Regeneron is provided as a powder for solution for injection in a glass vial.
Rilpivirin
Rilpivirine2
Rilpivirin + emtricitabin/ tenofovir- disoproxilfumarat n = 550
Rilpivirine + Emtricitabine/ Tenofovir disoproxil fumarate n = 550
Rilpivirin + emtricitabin/ tenofovirdisoproxilfumarat n = 550
Rilpivirine + Emtricitabine/Tenofovir disoproxil fumarate n = 550
Rilpivirin 150 mg x 1
150 mg once daily
rilpivirin AUC 1,12 (1,05-1,19) ↔ rilpivirin Cmax 1,04 (0,95-1,13) ↔ rilpivirin Cmin 1,25 (1,16-1,35)  simeprevir AUC 1,06 (0,94-1,19) ↔ simeprevir Cmax 1,10 (0,97-1,26)  simeprevir Cmin 0,96 (0,83-1,11) ↔
rilpivirine AUC 1.12 (1.05-1.19) ↔ rilpivirine Cmax 1.04 (0.95-1.13) ↔ rilpivirine Cmin 1.25 (1.16-1.35) ↑ simeprevir AUC 1.06 (0.94-1.19) ↔ simeprevir Cmax 1.10 (0.97-1.26) ↑ simeprevir Cmin 0.96 (0.83-1.11) ↔
rilpivirin AUC ↑ 13 % rilpivirin Cmin IR rilpivirin Cmax ↑ 21 %
rilpivirine AUC ↑ 13% rilpivirine Cmin NA rilpivirine Cmax ↑ 21
rilpivirin AUC ↑ 130 % rilpivirin Cmin ↑ 178 % rilpivirin Cmax ↑ 79 % darunavir AUC ↔ darunavir Cmin ↓ 11 % darunavir Cmax ↔
rilpivirine AUC ↑ 130% rilpivirine Cmin ↑ 178% rilpivirine Cmax ↑ 79% darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔
rilpivirin AUC ↑ 16 % rilpivirin Cmin ↔* rilpivirin Cmax ↑ 43 %
rilpivirine AUC ↑ 16%* rilpivirine Cmin ↔* rilpivirine Cmax ↑ 43
rilpivirin AUC ↓ 42 % rilpivirin Cmin ↓ 48 % rilpivirin Cmax ↓ 31 %
rilpivirine AUC ↓ 42% rilpivirine Cmin ↓ 48% rilpivirine Cmax ↓ 31
rilpivirin AUC ↓ 9 % rilpivirin Cmin IR rilpivirin Cmax ↔
rilpivirine AUC ↓ 9% rilpivirine Cmin NA rilpivirine Cmax ↔
Rilpivirin bør anvendes med forsigtighed til patienter med svært nedsat nyrefunktion eller terminal nyresygdom.
In patients with severe renal impairment or end-stage renal disease, rilpivirine should be used with caution.
Rilpivirin er et antiviralt middel, der også kaldes en non- nukleosid revers transkriptasehæmmer.
Rilpivirine is an antiviral agent called non-nucleoside reverse transcriptase inhibitor.
Rilpivirin er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh-klasse C).
Rilpivirine has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Rilpivirin har også vist antiviral aktivitet mod et bredt panel af hiv 1 gruppe M (undertype A, B, C, D, F, G, H) primære isolater med EC50–værdier fra 0,07 til 1,01 nM (0,03 til 0,37 ng/ml) og gruppe O primære isolater med EC50–værdier fra 2,88 til 8,45 nM (1,06 til 3,10 ng/ml).
Rilpivirine also demonstrated antiviral activity against a broad panel of HIV-1 group M (subtype A, B, C, D, F, G, H) primary isolates with EC50 values ranging from 0.07 to 1.01 nM (0.03 to 0.37 ng/ml) and group O primary isolates with EC50 values ranging from 2.88 to 8.45 nM (1.06 to 3.10 ng/ml).
Rilpivirin hæmmer ikke de humane cellulære dna-polymeraser α, β og mitokondrie-dna-polymerase γ.
Rilpivirine does not inhibit the human cellular DNA polymerases α, β and mitochondrial DNA polymerase γ.
Rilpivirin hæmmer ikke humane cellulære DNA- polymeraser α, β og γ.
Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.
Rilpivirin hæmmer P-glykoprotein in vitro (IC50 er 9,2 μM).
Rilpivirine inhibits P-glycoprotein in vitro (IC50 is 9.2 μM).
Rilpivirin inducerede ikke kromosomskader i in vivo–mikronukleustesten hos mus.
Rilpivirine did not induce chromosomal damage in the in vivo micronucleus test in mice.
Rilpivirin metaboliseres primært af cytokrom P450 (CYP)3A. Lægemidler, der inducerer eller hæmmer CYP3A, kan således påvirke clearance af rilpivirin (se pkt.
Rilpivirine is primarily metabolised by cytochrome P450 (CYP)3A. Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2).
Rilpivirin metaboliseres primært af cytokrom P450 (CYP3A).
Rilpivirine is primarily metabolised by cytochrome P450 (CYP3A).
Rilpivirin må ikke anvendes i kombination med produkter, der indeholder perikon, da samtidig indgift kan medføre tab af terapeutisk effekt af rilpivirin (se pkt.
Rilpivirine must not be used in combination with products containing St John’s wort as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3).
Rilpivirin må ikke anvendes i kombination med syrepumpe- hæmmere, da samtidig indgift sandsynligvis vil medføre tab af terapeutisk effekt af rilpivirin (se pkt.
Rilpivirine must not be used in combination with proton pump inhibitors as co-administration is likely to result in loss of therapeutic effect of rilpivirine (see section 4.3).
Rilpivirin 
Rilpivirine 
rilpivirin*
rilpivirine
Rilpivirin, en non-nukleosid revers transkriptasehæmmer (NNRTI).
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Rilpivirin-aktivitet medieres af ikke-kompetitiv hæmning af hiv 1 RT.
Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 RT.
Rilpivirin-resistente stammer blev udvalgt i cellekultur, der starter fra vildtype hiv 1 fra forskellige oprindelser og undertyper, samt NNRTI-resistent hiv 1.
Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI resistant HIV-1.
Rilpivirin2
Rilpivirine2
Rilpivirin:
Rifampicin/tenofovir disoproxil
Rilpivirin: AUC: ↑ 130%
Rilpivirine: AUC: ↑ 130
Rilpivirin: AUC: ↑ 16%*
Rilpivirine: AUC: ↑ 16
Rilpivirin: AUC: ↑ 49%
Rilpivirine: AUC: ↑ 49
Rilpivirin: AUC: ↑ 78%
Rilpivirine: AUC: ↑ 78
Rilpivirin: AUC: ↓ 40%
Rilpivirine: AUC: ↓ 40
Rilpivirin: AUC: ↓ 42%
Rilpivirine: AUC: ↓ 42
Rilpivirin: AUC: ↓ 80%
Rilpivirine: AUC: ↓ 80
Rilpivirinresistente mutationer observeredes hos 62,5 % (5/8) af forsøgspersonerne med virologisk svigt.
Rilpivirine resistance mutations were observed in 62.5% (5/8) of subjects with virological failure.
Rilpivirins farmakokinetik er ikke undersøgt hos patienter med nedsat nyrefunktion.
The pharmacokinetics of rilpivirine have not been studied in patients with renal insufficiency.
RILUTEK 50 mg filmovertrukne tabletter riluzol
RILUTEK 50 mg film-coated tablets riluzole
RILUTEK 50 mg filmovertrukne tabletter.
RILUTEK 50 mg film-coated tablets
RILUTEK 50 mg, filmovertrukne tabletter
RILUTEK 50 mg film-coated tablets
Rilutek anvendes til at forlænge patientens liv eller udskyde tidspunktet, hvor patienten skal i respirator.
Rilutek is used to extend the patient’s life or to delay the need for mechanical ventilation.
RILUTEK anvendes til patienter med amyotrofisk lateral sclerose (ALS).
RILUTEK is used in patients with amyotrophic lateral sclerosis (ALS).
RILUTEK forhindrer frigivelsen af glutamat og dette kan hjælpe med at forebygge, at nerveceller bliver ødelagt.
RILUTEK stops the release of glutamate and this may help in preventing the nerve cells being damaged.
RILUTEK fås i en pakning af 56 tabletter til oral anvendelse.
RILUTEK is available in a pack of 56 tablets to be taken orally.
Riluzol Zentiva fås i en pakning af 28, 56, 98, 112 eller 168 tabletter til oral anvendelse.
Riluzole Zentiva is available in a pack of 28, 56, 98, 112 or 168 tablets to be taken orally.
Riluzole Zentiva anvendes til at forlænge patientens liv eller den tid, der går, til patienten skal have mekanisk ventilation (respirator).
Riluzole Zentiva is used to extend the patient’s life, or the time before they need to use mechanical ventilation.
Riluzole Zentiva riluzol
Riluzole Zentiva riluzole
rimiterol og isoprenalin, som bruges til behandling af sygdomme i luftvejene
rimiterole and isoprenaline, used to treat respiratory diseases
rimiterol, isoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-methyldopa, apomorfin
rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine;
rimiterol, isoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, methyldopa, apomorphin
rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine;
rimiterol, isoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, metyldopa, apomorphin
rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine;
Rimonabant metaboliseres både via CYP3A og amidohydrolase (primært hepatisk) in vitro.
Rimonabant is metabolized by both CYP3A and amidohydrolase (predominantly hepatic) pathways in vitro.
Rimonabants farmakokinetik er ens i kvindelige og mandlige patienter.
The pharmacokinetics of rimonabant are similar in female and male patients.
Rindende næse
mediastinal
rindende næse
runny nose
Rindende næse
Vomiting, Nausea,
Rindende øjne
Watery eyes
Rindende øjne.
Excessive tear flow.
Ring straks til din læge, hvis dit barn viser tegn på træthed, kulde, bleghed, blålig hud, eller besvimelse, mens det tager HEMANGIOL.
Call your doctor right away if your child has any signs such as fatigue, coldness, pallor, bluish- coloured skin, or fainting while taking HEMANGIOL.
Ring straks til lægen, hvis De får symptomer såsom hovedpine, forvirring, kramper og synsforstyrrelser, med eller uden for højt blodtryk.
Get emergency help right away and call your doctor if you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.
Ring straks til lægen, ved symptomer som smerter eller trykken i brystet, smerter i armene, ryggen, nakken eller kæben, åndenød, følelsesløshed eller svaghed i den ene side af kroppen, problemer med at gå, hovedpine eller svimmelhed, mens du bliver behandlet med Sutent.
Call your doctor immediately if you get symptoms such as chest pain or pressure, pain in your arms, back, neck or jaw, shortness of breath, numbness or weakness on one side of your body, trouble talking, headache, or dizziness while on treatment with Sutent.
Ring til lægen eller få lægehjælp med det samme, hvis dit barn får nogen af de alvorlige bivirkninger, som er anført ovenfor, efter at have fået en dosis Synagis.
Call your doctor or get medical help right away if your child has any of the serious side effects listed above after receiving any dose of Synagis.
ringe knoglemarvsfunktion eller lavt antal blodlegemer (røde blodlegemer, hvide blodlegemer eller trombocytter) forårsaget af andre lidelser end rheumatoid arthritis eller arthritis psoriatica
poor bone marrow function or low blood cell counts (red cells, white cells or platelets) caused by conditions other than rheumatoid or psoriatic arthritis;
Ringe metabolisme: CYP2C19*2/*2, *2/*3 eller *3/*3
Poor metabolism: CYP2C19*2/*2, *2/*3 or *3/*3
Ringe metabolisme: CYP2C19*2/*2, *2/*3 eller 2
Poor metabolism: CYP2C19*2/*2, *2/*3 or *3/*3 2
Ringen eller brummen for øret, balanceproblemer
Ringing or buzzing noises in the ear, problems with balance
Ringen eller hylen for ørerne (tinnitus)
Ringing or noise in the ears (tinnitus)
ringen eller summen for ørerne (tinnitus), tab af høreevne
ringing or buzzing in the ears (tinnitus), loss of hearing
ringen eller summen for ørerne (tinnitus), tab af hørelse
ringing or buzzing in the ears (tinnitus), loss of hearing
ringen eller summen i ørerne (tinnitus), høretab,
ringing or buzzing in the ears (tinnitus), loss of hearing
ringen for ørene
ringing noise in ears
Ringen for ørene
Ringing sound in your ears
ringen for ørene (normalt forbigående), høretab, svimmelhed
ringing in the ears (normally transient), hearing loss, dizziness
Ringen for ørene (tinnitus)
Ringing in the ears
Ringen for ørene, ubehag i ørerne
Ringing in the ears, ear discomfort
Ringen for ørerne
Ringing in ears
ringen for ørerne
ringing in the ear
Ringen for ørerne
ringing in the ear,
Ringen for ørerne
ringing in the ears
ringen for ørerne
Ringing in the ears;
Ringen for ørerne
Ringing in your ears
ringen for ørerne
ringing noise in ears
Ringen for ørerne (tinnitus)
ringing in the ear,
ringen for ørerne (tinnitus)
ringing in the ears
Ringen for ørerne (tinnitus)
Ringing in the ears (tinnitus)
ringen for ørerne (tinnitus)
ringing in the ears,
Ringen for ørerne (tinnitus)
Ringing/sound in the ears (tinnitus)
ringen for ørerne (tinnitus), fornemmelse af, at alting drejer rundt
ringing in the ears, vertigo
ringen for ørerne (tinnitus).
ringing in the ears (tinnitus).
ringen for ørerne omtågethed
ringing in the ears feeling foggy in the head
Ringen for ørerne*
ringing in the ears
Ringen for ørerne, ubehag i ørerne
Ringing in the ears, ear discomfort
ringen for ørerne, øresmerter
ringing sound in the ears, ear pain
Ringen for ørerne; svimmelhed
Ringing in the ears; vertigo
ringen for øret
ears ringing
Ringen for øret
ringing in the ear
Ringen for øret
ringing sound in your ears
ringen/susen for ørerne (tinnitus)
ringing in the ears
ringende lyde i ørerne, døvhed
ringing sound in the ears, deafness
Ringer lactat injektionsvæske
Lactated Ringer's injection
Ringer lactat injektionsvæske, opløsning
Lactated Ringer's solution for injection
Ringer lactat injektionsvæske, opløsning
Lactated Ringer’s solution for injection
Ringer lactat injektionsvæske, opløsning
Lactated Ringer’s solution for injection.
Ringer lactat væske
Ringer's lactate solution
Ringer laktat, glucoseopløsning 50 mg/ml (5 %), natriumchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning, mannitol 200 mg/ml (20 %), thiopentalnatrium, etomidat, vecuroniumbromid, pancuroniumbromid, succinylcholin, atracuriumbesylat, mivacuriumchlorid, rocuroniumbromid, glycopyrrolatbromid, phenylephrin HCl, atropinsulfat, dopamin, noradrenalin, dobutamin, midazolam, morphinsulfat, fentanylcitrat og plasmaerstatning.
Lactated Ringers, 5% glucose solution, sodium chloride 9 mg/ml (0.9%) solution for injection, mannitol 200 mg/ml (20%), thiopental sodium, etomidate, vecuronium bromide, pancuronium bromide, succinylcholine, atracurium besylate, mivacurium chloride, rocuronium bromide, glycopyrrolate bromide, phenylephrine HCl, atropine sulfate, dopamine, noradrenaline, dobutamine, midazolam, morphine sulfate, fentanyl citrate, and a plasma-substitute.
Ringer-lactat-infusionsvæske
Lactated Ringer’s solution
Ringer-lactat-injektionsvæske
Keep this leaflet.
Ringer-lactat-injektionsvæske
Ringer-Lactate solution for injection.
Ringerlaktat injektionsvæske, opløsning
Lactated Ringer’s solution for injection
Ringers laktatopløsning
Ringer's lactate solution
Ringorm, en svampeinfektioner i hud (tinea versicolor)
Ringworm, a fungal infection of the skin (tinea versicolor)
Rinitis
embolism,
Rinorré
Rhinorrhea
Rinorré
Rhinorrhoea
Rinorré
Uncommon
Rinoré Almindelig
Rhinorrhoea Common
Riociguat genetablerer NO-sGC-cGMP-pathway og fører til en øget dannelse af cGMP.
Riociguat restores the NO-sGC-cGMP pathway and leads to increased generation of cGMP.
Riociguat IDT (n=228)
Riociguat IDT (n = 228)
Riociguat IDT (n=254)
Riociguat IDT (n = 254)
Riociguat og den primære metabolit er ikke hæmmere eller induktorer af primære CYP-isoformer (herunder CYP3A4) eller transportører (f.eks.
Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or transporters (e.g.
Riociguat og den primære metabolit er kraftige hæmmere af CYP1A1 in vitro.
Riociguat and its main metabolite are strong inhibitors of CYP1A1 in vitro.
Riociguat stimulerer den opløselige guanylatcyklase (sGC), der er et enzym i hjerte-kar-systemet inklusive lunger, og er receptoren for nitrogenoxid (NO).
Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO).
Riociguat stimulerer også sGC direkte, uafhængigt af NO.
Riociguat also directly stimulates sGC independently of NO.
Riociguat udskilles primært via cytokrom P450-medieret (CYP1A1, CYP3A4, CYP2C8, CYP2J2) oxidativ metabolisme, direkte biliær/fækal udskillelse af uændret riociguat, og nyreudskillelse af uændret riociguat via glomerulær filtration.
Riociguat is cleared mainly via cytochrome P450-mediated (CYP1A1, CYP3A4, CYP2C8, CYP2J2) oxidative metabolism, direct biliary/faecal excretion of unchanged riociguat and renal excretion of unchanged riociguat via glomerular filtration.
Riociguat: Prækliniske studier viste en additiv systemisk blodtrykssænkende virkning, når PDE5- hæmmere blev kombineret med riociguat.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Riom 63963, Clermont Ferrand Cedex 9 Frankrig
Riom 63963, Clermont Ferrand Cedex 9 France